Preoperative hemogram-related parameters to distinguish renal cell carcinoma from benign kidney masses: HERR score

Abstract

Objectives: Renal cell carcinoma (RCC) accounts for approximately 90% of all kidney malignancies, and it is difficult to preoperatively distinguish between tumors and benign masses without a kidney biopsy in small renal masses. We investigated whether any preoperatively defined hemogram-related parameters had a predictive value that would distinguish RCC from benign kidney masses using a novel scoring method.

Methods: Between January 2011 and November 2017, 330 patients diagnosed with kidney masses and who received an operation were included. Fifty-six masses were benign. The neutrophil-to-lymphocyte count (NLR), platelet-to-lymphocyte count, lymphocyte-to-monocyte count, mean platelet volume, platelet count ratio, and hemoglobin to red cell distribution width ratios were calculated. The hemogram-related parameters were combined with the tumor size to establish the hemogram-related risk (HERR) score. The area under the receiver operating characteristics curve, sensitivity, specificity, and likelihood ratios were evaluated to preoperatively diagnose RCC.

Results: Histological findings confirmed RCC in 274 patients. The NLR [median (interquartile range)] was higher in patients with RCC, 3.7 (4.7), compared to a benign kidney mass, 2.4 (2.2) (p < 0.001). A HERR score cut-off of ≥ 3 showed a good sensitivity at 78% with an LR+ of 10.8 [95% confidence interval (CI): 7.0-16.4] and an LR- of 1.2 (95% CI: 1.0-1.5).

Conclusion: Our study, despite being a preliminary validation, is the first to evaluate hemogram-related parameters for preoperatively discriminating between RCC and benign renal masses, and the HERR score serves as a potential diagnostic biomarker for this.

Keywords

• Renal cell carcinoma,kidney mass,hemogram-related risk score

References

1. [1] Siegel RL, Miller KD, Jemal A. Cancer statistics, 2016. CA. Cancer J Clin 66 2016;66:7-30.
2. [2] Tahbaz R, Schmid M, Merseburger AS. Prevention of kidney cancer incidence and recurrence: lifestyle, medication and nutrition. Curr Opin Urol 2018;28:62-79.
3. [3] Acar C, Sözen S, Üre I, Batur AF, Gürocak S, Küpeli B. Nephron-sparing treatments in small renal tumors: surgical and ablative procedures. Turk J Urol 2009;35:87-95.
4. [4] Özen H, Colowick A, Freiha FS. Incidentally discovered solid renal masses: what are they? Br J Urol 1993;72:274-6.
5. [5] Kay FU, Pedrosa I. Imaging of solid renal masses. Radiol Clin North Am 2017;55:243-58.
6. [6] Lane BR, Babineau D, Kattan MW, Novick AC, Gill IS, Zhou M, et al. A preoperative prognostic nomogram for solid enhancing renal tumors 7 cm or less amenable to partial nephrectomy. J Urol 2007;178:429-34.
7. [7] Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010;140:883-99.
8. [8] Hu K, Lou L, Ye J, Zhang S. Prognostic role of theneutrophil-lymphocyteratio in renal cell carcinoma: a meta-analysis. BMJ Open 2015;5:e006404.

9. [9] Wang X, Su S, Guo Y. The clinical use of the platelet to lymphocyte ratio and lymphocyte to monocyte ratio as prognostic factors in renal cell carcinoma: a systematic review and meta-analysis. Oncotarget 2017;8:84506-14.
10. [10] Sun P, Zhang F, Chen C, Bi X, Yang H, An X, et al. The ratio of hemoglobin to red cell distribution width as a novel prognostic parameter in esophageal squamous cell carcinoma: a retrospective study from southern China. Oncotarget 2016;5:42650-60.
11. [11] Prokopowicz G, Życzkowski M, Nowakowski K, Bogacki R, Bryniarski P, Paradysz A. Basic parameters of blood count as prognostic factors for renal cell carcinoma. Biomed Res Int 2016;2016:8687575.
12. [12] Golovastova MO, Korolev DO, Tsoy LV, Varshavsky VA, Xu WH, Vinarov AZ, et al. Biomarkers of renal tumors: the current state and clinical perspectives. Curr Urol Rep 2017;18:3.
13. [13] Gorgel SN, Ozer K, Kose O, Dindar AS. Can preoperative neutrophil lymphocyte ratio predict malignancy in patients undergoing partial nephrectomy because of renal mass? Int Braz J Urol 2017;43. doi: 10.1590/S1677-5538.IBJU.2017.0225.
14. [14] Viers BR, Thompson RH, Lohse CM, Cheville JC, Leibovich BC, Boorjian SA, et al. Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renaltumors. World J Urol 2016;34:1693-9.
15. [15] Stegner D, Dutting S, Nieswandt B. Mechanistic explanation for platelet contribution to cancer metastasis. Thromb Res 2014;2:149-57.
16. [16] Cho SY, Yang JJ, You E, Kim BH, Shim J, Lee HJ, et al. Mean platelet volume/platelet count ratio in hepatocellular carcinoma. Platelets 2013;24:375-7.
17. [17] Inagaki N, Kibata K, Tamaki T, Shimizu T, Nomura S. Prognostic impact of the mean platelet volume/platelet count ratio in terms of survival in advanced non-small cell lung cancer. Lung Cancer 2014;83:97-101.
18. [18] Budak YU, Polat M, Huysal K. The use of platelet indices, plateletcrit, mean platelet volume and platelet distribution width in emergency non-traumatic abdominal surgery: a systematic review. Biochem Med (Zagreb) 2016;26:178-93.